1
|
Grazioli A, Rabin J, Rector RP, Wu ZJ, Burke AP, Sharifai N, Shah A, Taylor BS, Gladwin MT. Venoarterial Extracorporeal Membrane Oxygenation Therapy in Patients with Sickle Cell Disease: Case Series and Review for Intensive Care Physicians. J Intensive Care Med 2024:8850666241260605. [PMID: 39140386 DOI: 10.1177/08850666241260605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/15/2024]
Abstract
Sickle cell disease (SCD) is associated with substantial morbidity and early mortality in afflicted adults. Cardiopulmonary complications that occur at increased frequency in SCD such as pulmonary embolism, pulmonary arterial hypertension, and acute chest syndrome can acutely worsen right ventricular function and lead to cardiogenic shock. Mechanical circulatory support including venoarterial extracorporeal membrane oxygenation (VA ECMO) is being increasingly utilized to treat hemodynamic collapse in various patient populations. However, a paucity of literature exists to guide the use of mechanical circulatory support in adults with SCD where disease-related sequela and unique hematologic aspects of this disorder may complicate extracorporeal therapy and must be understood. Here, we review the literature and describe three cases of adult patients with SCD who developed cardiogenic shock from acute decompensated right heart failure and were treated clinically with VA ECMO. Using an in vitro ECMO system, we investigate a potential increased risk of systemic fat emboli in patients with SCD who may be experiencing vaso-occlusive events with bone marrow involvement given the high-volume shunting of blood from venous to arterial systems with VA ECMO. The purpose of this study is to describe available extracorporeal life support experiences, review potential complications, and discuss the special considerations needed to further our understanding of the utility of VA ECMO in those with SCD.
Collapse
Affiliation(s)
- Alison Grazioli
- Department of Medicine, Division of Pulmonary and Critical Care Medicine, Program in Trauma, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Joseph Rabin
- Department of Surgery, Program in Trauma, University of Maryland School of Medicine, Baltimore, MD, USA
| | | | - Zhongjun J Wu
- Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Allen P Burke
- Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Nima Sharifai
- Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Aakash Shah
- Division of Cardiac Surgery, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Bradley S Taylor
- Division of Cardiac Surgery, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Mark T Gladwin
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
| |
Collapse
|
2
|
Nawaiseh MB, Yassin AM, Al-Sabbagh MQ, AlNawaiseh A, Zureigat H, Aljbour AlMajali D, Haddadin RR, El-Ghanem M, Abu-Rub M. Abnormal Neurologic Findings in Patients With Sickle Cell Disease Without a History of Major Neurologic Events. Neurol Clin Pract 2024; 14:e200215. [PMID: 38173541 PMCID: PMC10759091 DOI: 10.1212/cpj.0000000000200215] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2023] [Accepted: 09/12/2023] [Indexed: 01/05/2024]
Abstract
Background and Objectives Patients with sickle cell disease (SCD) are prone to symptomatic neurologic complications. Previous studies reported accrual of neural injury starting at early age, even without having symptomatic neurologic events. The aim of this study was to assess the prevalence and risk factors of abnormal neurologic findings in patients with SCD with no history of major symptomatic neurologic events. Methods Our study extracted patients diagnosed with SCD from the Cooperative Study of Sickle Cell Disease. Patients who underwent a neurologic evaluation were included in our analysis. Patients with previous documented major symptomatic neurologic events were excluded. We compared patients with SCD with abnormal neurologic findings with those without in terms of clinical and laboratory parameters using multivariate binary logistic regression. Results A total of 3,573 patients with SCD were included (median age = 11 [IQR = 19] years, male = 1719 [48.1%]). 519 (14.5%) patients had at least one abnormal neurologic finding. The most common findings in descending order were abnormal reflexes, gait abnormalities, cerebellar dysfunction, language deficits, nystagmus, abnormal muscle tone and strength, Romberg sign, Horner syndrome, and intellectual impairment. History of eye disease (odds ratio [OR] = 2.76, 95% confidence interval [CI] = 1.63-4.68) and history of osteomyelitis (OR = 2.55, 95% CI 1.34-4.84) were the strongest predictors of abnormal neurologic findings, followed by smoking (OR = 1.59, 95% CI 1.08-2.33), aseptic necrosis (OR = 1.57, 95% CI 1.06-2.33), hand-foot syndrome (OR = 1.48, 95% CI 1.04-2.12), and male sex (OR = 1.42, 95% CI 1.01-2.02). Discussion Neurologic deficits are relatively common in patients with SCD, even without documented major neurologic insults. They range from peripheral and ophthalmic deficits to central and cognitive disabilities. Patients with SCD should have early regular neurologic evaluations and risk factor modification, particularly actively promoting smoking cessation.
Collapse
Affiliation(s)
- Mohammed B Nawaiseh
- Department of Ophthalmology (MBN), Jordanian Royal Medical Services, Amman; Department of Neurology (AMY), Jordan University of Science and Technology, Irbid, Jordan; Department of Neurology (MQAS), Kansas University Medical Center, Kansas City; Department of Internal Medicine (AA), St. Elizabeth's Medical Center, Boston, MA; Department of Internal Medicine (HZ), Cleveland Clinic, OH; Department of Internal Medicine (DAA), Henry Ford Health System, Detroit, MI; Department of Internal Medicine (RRH), JCESOM, Marshall University, WV; Department of Clinical Sciences (ME-G), College of Medicine, University of Houston, HCA Northwest Medical Center, Houston, TX; and Department of Neurology (MA-R), George Washington University, Washington, DC
| | - Ahmed M Yassin
- Department of Ophthalmology (MBN), Jordanian Royal Medical Services, Amman; Department of Neurology (AMY), Jordan University of Science and Technology, Irbid, Jordan; Department of Neurology (MQAS), Kansas University Medical Center, Kansas City; Department of Internal Medicine (AA), St. Elizabeth's Medical Center, Boston, MA; Department of Internal Medicine (HZ), Cleveland Clinic, OH; Department of Internal Medicine (DAA), Henry Ford Health System, Detroit, MI; Department of Internal Medicine (RRH), JCESOM, Marshall University, WV; Department of Clinical Sciences (ME-G), College of Medicine, University of Houston, HCA Northwest Medical Center, Houston, TX; and Department of Neurology (MA-R), George Washington University, Washington, DC
| | - Mohammed Q Al-Sabbagh
- Department of Ophthalmology (MBN), Jordanian Royal Medical Services, Amman; Department of Neurology (AMY), Jordan University of Science and Technology, Irbid, Jordan; Department of Neurology (MQAS), Kansas University Medical Center, Kansas City; Department of Internal Medicine (AA), St. Elizabeth's Medical Center, Boston, MA; Department of Internal Medicine (HZ), Cleveland Clinic, OH; Department of Internal Medicine (DAA), Henry Ford Health System, Detroit, MI; Department of Internal Medicine (RRH), JCESOM, Marshall University, WV; Department of Clinical Sciences (ME-G), College of Medicine, University of Houston, HCA Northwest Medical Center, Houston, TX; and Department of Neurology (MA-R), George Washington University, Washington, DC
| | - Ahmad AlNawaiseh
- Department of Ophthalmology (MBN), Jordanian Royal Medical Services, Amman; Department of Neurology (AMY), Jordan University of Science and Technology, Irbid, Jordan; Department of Neurology (MQAS), Kansas University Medical Center, Kansas City; Department of Internal Medicine (AA), St. Elizabeth's Medical Center, Boston, MA; Department of Internal Medicine (HZ), Cleveland Clinic, OH; Department of Internal Medicine (DAA), Henry Ford Health System, Detroit, MI; Department of Internal Medicine (RRH), JCESOM, Marshall University, WV; Department of Clinical Sciences (ME-G), College of Medicine, University of Houston, HCA Northwest Medical Center, Houston, TX; and Department of Neurology (MA-R), George Washington University, Washington, DC
| | - Hadil Zureigat
- Department of Ophthalmology (MBN), Jordanian Royal Medical Services, Amman; Department of Neurology (AMY), Jordan University of Science and Technology, Irbid, Jordan; Department of Neurology (MQAS), Kansas University Medical Center, Kansas City; Department of Internal Medicine (AA), St. Elizabeth's Medical Center, Boston, MA; Department of Internal Medicine (HZ), Cleveland Clinic, OH; Department of Internal Medicine (DAA), Henry Ford Health System, Detroit, MI; Department of Internal Medicine (RRH), JCESOM, Marshall University, WV; Department of Clinical Sciences (ME-G), College of Medicine, University of Houston, HCA Northwest Medical Center, Houston, TX; and Department of Neurology (MA-R), George Washington University, Washington, DC
| | - Dina Aljbour AlMajali
- Department of Ophthalmology (MBN), Jordanian Royal Medical Services, Amman; Department of Neurology (AMY), Jordan University of Science and Technology, Irbid, Jordan; Department of Neurology (MQAS), Kansas University Medical Center, Kansas City; Department of Internal Medicine (AA), St. Elizabeth's Medical Center, Boston, MA; Department of Internal Medicine (HZ), Cleveland Clinic, OH; Department of Internal Medicine (DAA), Henry Ford Health System, Detroit, MI; Department of Internal Medicine (RRH), JCESOM, Marshall University, WV; Department of Clinical Sciences (ME-G), College of Medicine, University of Houston, HCA Northwest Medical Center, Houston, TX; and Department of Neurology (MA-R), George Washington University, Washington, DC
| | - Rund R Haddadin
- Department of Ophthalmology (MBN), Jordanian Royal Medical Services, Amman; Department of Neurology (AMY), Jordan University of Science and Technology, Irbid, Jordan; Department of Neurology (MQAS), Kansas University Medical Center, Kansas City; Department of Internal Medicine (AA), St. Elizabeth's Medical Center, Boston, MA; Department of Internal Medicine (HZ), Cleveland Clinic, OH; Department of Internal Medicine (DAA), Henry Ford Health System, Detroit, MI; Department of Internal Medicine (RRH), JCESOM, Marshall University, WV; Department of Clinical Sciences (ME-G), College of Medicine, University of Houston, HCA Northwest Medical Center, Houston, TX; and Department of Neurology (MA-R), George Washington University, Washington, DC
| | - Mohammad El-Ghanem
- Department of Ophthalmology (MBN), Jordanian Royal Medical Services, Amman; Department of Neurology (AMY), Jordan University of Science and Technology, Irbid, Jordan; Department of Neurology (MQAS), Kansas University Medical Center, Kansas City; Department of Internal Medicine (AA), St. Elizabeth's Medical Center, Boston, MA; Department of Internal Medicine (HZ), Cleveland Clinic, OH; Department of Internal Medicine (DAA), Henry Ford Health System, Detroit, MI; Department of Internal Medicine (RRH), JCESOM, Marshall University, WV; Department of Clinical Sciences (ME-G), College of Medicine, University of Houston, HCA Northwest Medical Center, Houston, TX; and Department of Neurology (MA-R), George Washington University, Washington, DC
| | - Mohammad Abu-Rub
- Department of Ophthalmology (MBN), Jordanian Royal Medical Services, Amman; Department of Neurology (AMY), Jordan University of Science and Technology, Irbid, Jordan; Department of Neurology (MQAS), Kansas University Medical Center, Kansas City; Department of Internal Medicine (AA), St. Elizabeth's Medical Center, Boston, MA; Department of Internal Medicine (HZ), Cleveland Clinic, OH; Department of Internal Medicine (DAA), Henry Ford Health System, Detroit, MI; Department of Internal Medicine (RRH), JCESOM, Marshall University, WV; Department of Clinical Sciences (ME-G), College of Medicine, University of Houston, HCA Northwest Medical Center, Houston, TX; and Department of Neurology (MA-R), George Washington University, Washington, DC
| |
Collapse
|
8
|
Stotesbury H, Kawadler JM, Hales PW, Saunders DE, Clark CA, Kirkham FJ. Vascular Instability and Neurological Morbidity in Sickle Cell Disease: An Integrative Framework. Front Neurol 2019; 10:871. [PMID: 31474929 PMCID: PMC6705232 DOI: 10.3389/fneur.2019.00871] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2019] [Accepted: 07/26/2019] [Indexed: 12/20/2022] Open
Abstract
It is well-established that patients with sickle cell disease (SCD) are at substantial risk of neurological complications, including overt and silent stroke, microstructural injury, and cognitive difficulties. Yet the underlying mechanisms remain poorly understood, partly because findings have largely been considered in isolation. Here, we review mechanistic pathways for which there is accumulating evidence and propose an integrative systems-biology framework for understanding neurological risk. Drawing upon work from other vascular beds in SCD, as well as the wider stroke literature, we propose that macro-circulatory hyper-perfusion, regions of relative micro-circulatory hypo-perfusion, and an exhaustion of cerebral reserve mechanisms, together lead to a state of cerebral vascular instability. We suggest that in this state, tissue oxygen supply is fragile and easily perturbed by changes in clinical condition, with the potential for stroke and/or microstructural injury if metabolic demand exceeds tissue oxygenation. This framework brings together recent developments in the field, highlights outstanding questions, and offers a first step toward a linking pathophysiological explanation of neurological risk that may help inform future screening and treatment strategies.
Collapse
Affiliation(s)
- Hanne Stotesbury
- Developmental Neurosciences, UCL Great Ormond Institute of Child Health, London, United Kingdom
| | - Jamie M Kawadler
- Developmental Neurosciences, UCL Great Ormond Institute of Child Health, London, United Kingdom
| | - Patrick W Hales
- Developmental Neurosciences, UCL Great Ormond Institute of Child Health, London, United Kingdom
| | - Dawn E Saunders
- Developmental Neurosciences, UCL Great Ormond Institute of Child Health, London, United Kingdom.,Department of Radiology, Great Ormond Hospital, London, United Kingdom
| | - Christopher A Clark
- Developmental Neurosciences, UCL Great Ormond Institute of Child Health, London, United Kingdom
| | - Fenella J Kirkham
- Developmental Neurosciences, UCL Great Ormond Institute of Child Health, London, United Kingdom.,Clinical and Experimental Sciences, University of Southampton, Southampton, United Kingdom.,Department of Child Health, University Hospital Southampton, Southampton, United Kingdom.,Department of Paediatric Neurology, Kings College Hospital NHS Foundation Trust, London, United Kingdom
| |
Collapse
|